Theranexus Société Anonyme (ALTHX.PA)
EUR 0.64
(32.37%)
EUR 0.64
(32.37%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -6.82 Million EUR | -3.97% |
| 2022 | -6.56 Million EUR | 19.43% |
| 2021 | -8.15 Million EUR | -69.89% |
| 2020 | -4.79 Million EUR | 14.02% |
| 2019 | -5.57 Million EUR | -5.27% |
| 2018 | -5.3 Million EUR | -150.64% |
| 2017 | -2.11 Million EUR | -33.28% |
| 2016 | -1.58 Million EUR | -205.95% |
| 2015 | -518.65 Thousand EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 100.8 Thousand EUR | 0.0% |
| 2023 Q4 | -3.18 Million EUR | 0.0% |
| 2023 FY | -6.82 Million EUR | -3.97% |
| 2023 Q2 | -3.64 Million EUR | 0.0% |
| 2022 Q4 | -3.27 Million EUR | 0.0% |
| 2022 FY | -6.56 Million EUR | 19.43% |
| 2022 Q2 | -3.28 Million EUR | 0.0% |
| 2021 Q2 | -3.72 Million EUR | 0.0% |
| 2021 FY | -8.15 Million EUR | -69.89% |
| 2021 Q4 | -4.42 Million EUR | 0.0% |
| 2020 Q4 | -1.92 Million EUR | 0.0% |
| 2020 FY | -4.79 Million EUR | 14.02% |
| 2020 Q2 | -2.86 Million EUR | 0.0% |
| 2019 FY | -5.57 Million EUR | -5.27% |
| 2019 Q4 | -2.8 Million EUR | 0.0% |
| 2019 Q2 | -2.77 Million EUR | 0.0% |
| 2018 FY | -5.3 Million EUR | -150.64% |
| 2018 Q4 | -3.24 Million EUR | 0.0% |
| 2018 Q2 | -2.05 Million EUR | 0.0% |
| 2017 FY | -2.11 Million EUR | -33.28% |
| 2017 Q4 | -1.4 Million EUR | 0.0% |
| 2017 Q1 | -528.7 Thousand EUR | 41.26% |
| 2017 Q2 | -709.67 Thousand EUR | -34.23% |
| 2016 Q2 | -686.78 Thousand EUR | -73.29% |
| 2016 FY | -1.58 Million EUR | -205.95% |
| 2016 Q1 | -396.3 Thousand EUR | 0.0% |
| 2016 Q4 | -900.01 Thousand EUR | 0.0% |
| 2015 Q2 | -129.66 Thousand EUR | 0.0% |
| 2015 Q3 | -129.66 Thousand EUR | 0.0% |
| 2015 Q4 | -396.3 Thousand EUR | -205.64% |
| 2015 FY | -518.65 Thousand EUR | 0.0% |
| 2015 Q1 | -129.66 Thousand EUR | 0.0% |
| 2014 Q4 | -129.66 Thousand EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -94.086% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 95.378% |
| Adocia SA | -21.16 Million EUR | 67.735% |
| Aelis Farma SA | -5.07 Million EUR | -34.461% |
| Biophytis S.A. | -17.02 Million EUR | 59.897% |
| Advicenne S.A. | -7.03 Million EUR | 2.888% |
| genOway Société anonyme | 1.56 Million EUR | 535.574% |
| IntegraGen SA | -171.39 Thousand EUR | -3883.659% |
| Medesis Pharma S.A. | -3.95 Million EUR | -72.445% |
| Neovacs S.A. | -8.74 Million EUR | 21.908% |
| NFL Biosciences SA | -3.74 Million EUR | -82.299% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 8724.527% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -115.328% |
| Sensorion SA | -22.06 Million EUR | 69.053% |
| TME Pharma N.V. | -6.73 Million EUR | -1.365% |
| Valbiotis SA | -7.36 Million EUR | 7.33% |
| TheraVet SA | -1.57 Million EUR | -334.706% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 66.438% |
| argenx SE | -272.91 Million EUR | 97.498% |
| BioSenic S.A. | -28.77 Million EUR | 76.274% |
| Celyad Oncology SA | -8.44 Million EUR | 19.177% |
| DBV Technologies S.A. | -67.26 Million EUR | 89.85% |
| Galapagos NV | 211.69 Million EUR | 103.225% |
| Genfit S.A. | -28.89 Million EUR | 76.369% |
| GeNeuro SA | -14.75 Million EUR | 53.731% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | 55.605% |
| Innate Pharma S.A. | -7.57 Million EUR | 9.802% |
| Inventiva S.A. | -110.42 Million EUR | 93.817% |
| MaaT Pharma SA | -19.71 Million EUR | 65.37% |
| MedinCell S.A. | -25.03 Million EUR | 72.73% |
| Nanobiotix S.A. | -39.7 Million EUR | 82.801% |
| Onward Medical N.V. | -36.18 Million EUR | 81.128% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -103.641% |
| OSE Immunotherapeutics SA | -23 Million EUR | 70.317% |
| Oxurion NV | -18.96 Million EUR | 64.005% |
| Pharming Group N.V. | -9.75 Million EUR | 30.017% |
| Poxel S.A. | -35.09 Million EUR | 80.542% |
| GenSight Biologics S.A. | -26.22 Million EUR | 73.959% |
| Transgene SA | -22.32 Million EUR | 69.42% |
| Financière de Tubize SA | 88.15 Million EUR | 107.746% |
| UCB SA | 343 Million EUR | 101.991% |
| Valneva SE | -101.42 Million EUR | 93.268% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 75.909% |